

Sophie Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7427097/publications.pdf>

Version: 2024-02-01

101
papers

4,651
citations

94433

37
h-index

98798

67
g-index

103
all docs

103
docs citations

103
times ranked

5486
citing authors

#	ARTICLE	IF	CITATIONS
1	Acquired von Willebrand syndrome secondary to lymphoproliferative disorders: A case series from two French centers. <i>Thrombosis Research</i> , 2022, 209, 1-4.	1.7	1
2	A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. <i>British Journal of Haematology</i> , 2022, 198, 535-544.	2.5	12
3	Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM). <i>Transfusion</i> , 2022, 62, 961-973.	1.6	5
4	Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression for ruling out myelodysplastic syndromes: a prospective validation study. <i>Annals of Hematology</i> , 2021, 100, 1149-1158.	1.8	3
5	Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk". <i>Blood</i> , 2021, 138, 1842-1842.	1.4	2
6	CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM. <i>Blood</i> , 2021, 138, 243-243.	1.4	18
7	Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group. <i>Blood</i> , 2021, 138, 62-62.	1.4	23
8	NOX4 is the main NADPH oxidase involved in the early stages of hematopoietic differentiation from human induced pluripotent stem cells. <i>Free Radical Biology and Medicine</i> , 2020, 146, 107-118.	2.9	15
9	The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. <i>Annals of Hematology</i> , 2020, 99, 7-19.	1.8	13
10	Impact of transfusion on survival in patients with myelodysplastic syndromes: Current knowledge, new insights and transfusion clinical practice. <i>Blood Reviews</i> , 2020, 41, 100649.	5.7	10
11	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. <i>Hemato</i> , 2020, 1, 10-22.	0.6	0
12	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis-stimulating agents. <i>Leukemia Research</i> , 2020, 99, 106472.	0.8	4
13	Extracellular vesicles from myelodysplastic mesenchymal stromal cells induce DNA damage and mutagenesis of hematopoietic stem cells through miRNA transfer. <i>Leukemia</i> , 2020, 34, 2249-2253.	7.2	11
14	A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	55
15	Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes: a diagnostic accuracy study. <i>Haematologica</i> , 2019, 104, 2382-2390.	3.5	7
16	Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate. <i>Blood Advances</i> , 2019, 3, 1868-1880.	5.2	8
17	Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-risk myelodysplastic syndrome: a systematic literature review. <i>British Journal of Haematology</i> , 2019, 184, 134-160.	2.5	37
18	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2019, 104, 497-504.	3.5	17

#	ARTICLE	IF	CITATIONS
19	Chronic Myelogenous Leukemia: Pathology and Genetics, Diagnosis and Treatment. , 2018, , 418-418.		0
20	Acute Myelogeneous Leukemia: Diagnosis and Treatment. , 2018, , 9-9.		0
21	Acute Lymphocytic Leukemia: Diagnosis and Treatment . , 2018, , 1-1.		0
22	Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes. Oncotarget, 2018, 9, 14993-15000.	1.8	8
23	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2017, 35, 1591-1597.	1.6	79
24	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget, 2017, 8, 37866-37874.	1.8	10
25	Reactive oxygen species levels control NF- κ B activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. Oncotarget, 2017, 8, 105510-105524.	1.8	35
26	Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?. Haematologica, 2016, 101, e280-e283.	3.5	41
27	A randomized phase II trial of azacitidine +/- epoetin- α in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica, 2016, 101, 918-925.	3.5	55
28	Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. British Journal of Haematology, 2016, 174, 730-747.	2.5	37
29	Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. Leukemia Research, 2016, 47, 136-141.	0.8	49
30	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology, 2016, 55, 291-300.	1.9	170
31	Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research, 2016, 43, 13-17.	0.8	87
32	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry. Blood, 2016, 128, 3186-3186.	1.4	14
33	Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia Research, 2015, 39, 501-504.	0.8	46
34	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. Blood, 2015, 126, 2872-2872.	1.4	1
35	Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry. Blood, 2015, 126, 1677-1677.	1.4	0
36	Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA). Blood, 2015, 126, 2893-2893.	1.4	0

#	ARTICLE	IF	CITATIONS
37	A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. <i>Leukemia</i> , 2013, 27, 1479-1486.	7.2	50
38	Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. <i>Leukemia</i> , 2013, 27, 1981-1987.	7.2	78
39	Is it time for 5-azacytidine combinations in high-risk myelodysplastic syndrome patients?. <i>Expert Review of Hematology</i> , 2013, 6, 39-42.	2.2	0
40	Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. <i>Leukemia and Lymphoma</i> , 2013, 54, 767-777.	1.3	49
41	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. <i>Leukemia</i> , 2013, 27, 1401-1403.	7.2	102
42	Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. <i>European Journal of Haematology</i> , 2013, 90, 355-364.	2.2	66
43	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2662-2670.	1.6	265
44	Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. <i>British Journal of Haematology</i> , 2013, 161, 738-740.	2.5	8
45	Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. <i>Leukemia</i> , 2013, 27, 1283-1290.	7.2	65
46	A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). <i>Leukemia</i> , 2013, 27, 1610-1613.	7.2	31
47	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. <i>Blood</i> , 2013, 122, 3169-3177.	1.4	169
48	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. <i>Blood</i> , 2013, 122, 2286-2288.	1.4	67
49	Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM. <i>Blood</i> , 2013, 122, 658-658.	1.4	1
50	The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, DÄ¼sseldorf Registry and Fism. <i>Blood</i> , 2013, 122, 2761-2761.	1.4	1
51	The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. <i>Leukemia</i> , 2012, 26, 1195-1202.	7.2	138
52	Salvage therapy of Autoimmune Thrombocytopenic Purpura revealing non-Hodgkin Lymphoma by the thrombopoietin receptor agonist romiplostim. <i>British Journal of Haematology</i> , 2012, 156, 145-147.	2.5	7
53	The eukaryotic Initiating Factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 156, 547-550.	2.5	5
54	Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf) Tj ETQq0 0 0 tgeBT /Overlock 10 Tf		

#	ARTICLE	IF	CITATIONS
55	Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2012, 120, 3830-3830.	1.4	6
56	Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn) Tj ETQq0 0,0 rgBT /Overlock 10	1.4	4
57	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 1697-1697.	1.4	0
58	Heterogeneous sensitivity of human acute myeloid leukemia to β -catenin down-modulation. <i>Leukemia</i> , 2011, 25, 770-780.	7.2	54
59	The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases. <i>British Journal of Haematology</i> , 2011, 153, 664-665.	2.5	37
60	Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. <i>Leukemia Research</i> , 2011, 35, 1530-1533.	0.8	16
61	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. <i>Leukemia Research</i> , 2011, 35, 863-867.	0.8	44
62	Leukemic phase of follicular lymphomas: an atypical presentation. <i>Leukemia and Lymphoma</i> , 2011, 52, 1504-1508.	1.3	15
63	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. <i>Blood</i> , 2011, 118, 115-115.	1.4	16
64	Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry. <i>Blood</i> , 2011, 118, 2775-2775.	1.4	20
65	RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age. <i>Blood</i> , 2011, 118, 945-945.	1.4	0
66	Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. <i>Haematologica</i> , 2010, 95, 415-423.	3.5	129
67	β kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. <i>Blood</i> , 2010, 116, 4240-4250.	1.4	69
68	The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. <i>Blood</i> , 2010, 116, 4262-4273.	1.4	173
69	p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. <i>Haematologica</i> , 2010, 95, 1964-1968.	3.5	30
70	Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients. <i>Leukemia Research</i> , 2010, 34, 1430-1436.	0.8	60
71	The dual PI3K/mTOR inhibitor, NVP-BE2235, is efficacious against follicular lymphoma. <i>Leukemia</i> , 2010, 24, 1781-1784.	7.2	57
72	Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. <i>Leukemia</i> , 2010, 24, 1686-1699.	7.2	100

#	ARTICLE	IF	CITATIONS
73	Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide. <i>Leukemia</i> , 2010, 24, 1960-1962.	7.2	7
74	Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5424-5435.	7.0	146
75	Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 819-828.	3.5	240
76	Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination. <i>Leukemia and Lymphoma</i> , 2010, 51, 2288-2290.	1.3	7
77	Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs). <i>Blood</i> , 2010, 116, 442-442.	1.4	1
78	Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients. A Report by the Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2010, 116, 2916-2916.	1.4	0
79	C034 Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS. <i>Leukemia Research</i> , 2009, 33, S51-S52.	0.8	0
80	Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, 547-550.	0.8	18
81	Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. <i>Blood</i> , 2009, 114, 1618-1627.	1.4	169
82	Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. <i>Leukemia Research</i> , 2008, 32, 1049-1053.	0.8	75
83	PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. <i>Leukemia</i> , 2008, 22, 1698-1706.	7.2	170
84	Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. <i>Leukemia and Lymphoma</i> , 2008, 49, 2012-2014.	1.3	23
85	Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. <i>Blood</i> , 2008, 111, 379-382.	1.4	234
86	Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. <i>Blood</i> , 2008, 111, 574-582.	1.4	295
87	Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. <i>Blood</i> , 2007, 110, 1025-1028.	1.4	129
88	P149 Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): current results of the French ATU program. <i>Leukemia Research</i> , 2007, 31, S122.	0.8	1
89	Effect of spacing intravenous bisphosphonates in patients with multiple myeloma in plateau phase. <i>Leukemia</i> , 2007, 21, 1596-1599.	7.2	2
90	Rational for Specific Inhibition of Both PI3K/AKT and mTORC1 Activities in Acute Myelogenous Leukaemia. <i>Blood</i> , 2006, 108, 1904-1904.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.. Blood, 2006, 108, 2664-2664.	1.4	4
92	Treatment of Myelodysplastic Syndromes with del 5q before the Lenalidomide Era: The GFM Experience.. Blood, 2006, 108, 2678-2678.	1.4	3
93	Constitutive Phosphoinositide-3kinase Activation Represents a Good Prognostic Factor in De Novo AML Patients under 60 Years.. Blood, 2006, 108, 1895-1895.	1.4	2
94	Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood, 2005, 105, 4035-4042.	1.4	58
95	Erythroleukaemia and RAEB-t: a same disease?. Leukemia, 2004, 18, 888-890.	7.2	13
96	Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia, 2004, 18, 1711-1716.	7.2	114
97	Varicella-Zoster Viral Meningitis Mimicking Lymphoma. Leukemia and Lymphoma, 2003, 44, 1793-1795.	1.3	3
98	Erythroleukemia: a comparison between the previous FAB approach and the WHO classification. Leukemia Research, 2002, 26, 423-429.	0.8	32
99	Erythroleukemia: a need for a new definition. Leukemia, 2002, 16, 1399-1401.	7.2	44
100	Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplantation, 2000, 26, 321-326.	2.4	30
101	Pure red cell aplasia associated with myelodysplastic syndromes. Leukemia, 2000, 14, 1709-1710.	7.2	19